<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367716</url>
  </required_header>
  <id_info>
    <org_study_id>SJM- CIP-CRD 733</org_study_id>
    <nct_id>NCT02367716</nct_id>
  </id_info>
  <brief_title>Post-market Study of Multi-Vector Left Ventricular Lead Performance in Chinese Patients With Chronic Heart Failure</brief_title>
  <acronym>MVLV</acronym>
  <official_title>Post-market Study of Multi-Vector Left Ventricular Lead Performance in Chinese Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to observe the safety and efficacy of the multi-vector&#xD;
      left ventricular (LV) lead in Chinese patients that are indicated for Cardiac&#xD;
      Resynchronization Therapy (CRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, non-randomized observational study.&#xD;
&#xD;
      The total duration of the study is expected to be 2.5 years. The clinical study will be&#xD;
      conducted in no more than 15 centers in China. Approximately 120 subjects will be enrolled in&#xD;
      this study. Subjects will be followed up at 3, 6, 12 months and every 6 months afterwards.&#xD;
      All subjects need to be followed for at least 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)</measure>
    <time_frame>From implantation to 6 months after implant procedure.</time_frame>
    <description>The primary safety endpoint is the number of participants with LV lead-related SADEs compared to the total number of analyzed participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Effective LV Pacing</measure>
    <time_frame>6 months</time_frame>
    <description>The effectiveness endpoint is the number of participants with effective LV pacing compared to the total number of analyzed participants. The following must be met to be considered effective LV pacing:&#xD;
Pacing threshold (immediately after implant): for pacing threshold at a pulse width of 0.5 ms, the voltage must be ≤3.5 Voltage (V) in any LV lead vector.&#xD;
Pacing stability (pre-discharge, 3 months and 6 months after implant): for pacing threshold at a pulse width of 0.5 ms, the voltage must be ≤6.0V in any LV lead vector.&#xD;
Pacing impedance (immediately after implant): Impedance value in any LV lead vector must be in the normal range of 200-2000 ohm (Ω).&#xD;
Table 9: Impedance stability (pre-discharge, 3 months and 6 months after implant): Impedance value in any LV lead vector must be in the normal range of 200-2000Ω.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants in Each NYHA Functional Class</measure>
    <time_frame>6 months</time_frame>
    <description>This secondary objective is to count the number of participants in each NYHA functional class at 6 months; NYHA classification is determined by a physician and measures the severity of a patient's heart failure by evaluating heart failure symptoms and limitations. Class I patients have mild heart failure symptoms, while patients with Class IV have severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Intrinsic QRS Duration of Participants</measure>
    <time_frame>6 months</time_frame>
    <description>This secondary objective is to measure the intrinsic QRS duration of participants at 6 months.</description>
  </secondary_outcome>
  <enrollment type="Actual">121</enrollment>
  <condition>Chronic Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT</intervention_name>
    <description>The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A patient meets the current ESC or ACCF/AHA/HRS Class I or Class IIa indications for CRT&#xD;
        implant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets the current European Society of Cardiology (ESC) or American College of&#xD;
             Cardiology Foundation (ACCF)/American Heart Association (AHA)/Heart Rhythm Society&#xD;
             (HRS) Class I or Class IIa indications for CRT implant (including upgrades from single&#xD;
             or dual chamber Implantable Cardioverter-Defibrillators (ICDs))&#xD;
&#xD;
          -  Are ≥ 18 years of age at the time of enrolment.&#xD;
&#xD;
          -  Are able to provide written Informed Consent prior to any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who is unable to comply with the follow-up schedule.&#xD;
&#xD;
          -  Patient who has any medical conditions that in the opinion of the investigator will&#xD;
             not be appropriate to participate in the study .&#xD;
&#xD;
          -  Patient has a life expectancy of less than 1 year due to any condition.&#xD;
&#xD;
          -  Patients, who has a CRT device implanted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clay Cohorn</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second Affliated hospital Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second Affiliated hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510235</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital Affiliated to Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Greentown cardiovascular hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated hospital of Medical College of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second Affiliated hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Runrun Shaw Hospital College of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rui Jin hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>October 26, 2018</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm- St. Jude Medical Quartet™ LV Lead Model 1458Q</title>
          <description>This post-market study was conducted as required by China FDA to characterize the safety and efficacy of the commercial St. Jude Medical (SJM) Quartet™ Left Ventricular (LV) lead model 1458Q implanted with any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).&#xD;
This is a single arm study.&#xD;
The first subject was enrolled on December 25, 2014 and the last subject was enrolled on March 25, 2016.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 121 patients were recruited at 13 sites. However, one subject who was retrospectively enrolled after an existing implant did not meet inclusion criteria and therefore was not included in analyses as the subject was withdrawn by the investigator.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>This post-market study was conducted as required by China FDA to characterize the safety and efficacy of the commercial SJM Quartet™ LV lead model 1458Q implanted with any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).&#xD;
This is a single arm study.&#xD;
The first subject was enrolled on December 25, 2014 and the last subject was enrolled on March 25, 2016.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>A total of 121 subjects were enrolled at 13 sites. However, one subject who was retrospectively enrolled after an existing implant did not meet inclusion criteria and therefore was not included in analyses as the subject was withdrawn by the investigator.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>A total of 121 subjects were enrolled at 13 sites. However, one subject who was retrospectively enrolled after an existing implant did not meet inclusion criteria and therefore was not included in analyses as the subject was withdrawn by the investigator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class, n (%)</title>
          <population>NYHA classification is determined by a physician and measures the severity of a patient's heart failure by evaluating heart failure symptoms and limitations. Class I patients have mild heart failure symptoms, while patients with Class IV have severe symptoms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Done</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intrinsic QRS Duration</title>
          <population>A total of 113 patients had intrinsic QRS duration measured at baseline and are included in the analysis population.</population>
          <units>milliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Cause of Cardiac Disease, n (%)</title>
          <population>A total of 121 subjects were enrolled at 13 sites. However, one subject who was retrospectively enrolled after an existing implant did not meet inclusion criteria and therefore was not included in analyses as the subject was withdrawn by the investigator</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Ischemic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Ischemic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Cardiac Interventions, n (%)</title>
          <description>Due to characters limitation for Row &quot;PTCA/Stents/Atherectomy&quot;, the acronym &quot;PTCA&quot; stands for percutaneous transluminal coronary angiography.</description>
          <population>A total of 121 subjects were enrolled at 13 sites. However, one subject who was retrospectively enrolled after an existing implant did not meet inclusion criteria and therefore was not included in analyses as the subject was withdrawn by the investigator</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Coronary Artery Bypass Graft</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTCA/Stents/Atherectomy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Medications, n (%)</title>
          <population>A total of 121 subjects were enrolled at 13 sites. However, one subject who was retrospectively enrolled after an existing implant did not meet inclusion criteria and therefore was not included in analyses as the subject was withdrawn by the investigator</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ACE Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adrenergics</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonist</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin Receptor Blocker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Arrhythmics</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anticoagulants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiplatelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Channel Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Glycosides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretics</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrates</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Statins</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)</title>
        <description>The primary safety endpoint is the number of participants with LV lead-related SADEs compared to the total number of analyzed participants.</description>
        <time_frame>From implantation to 6 months after implant procedure.</time_frame>
        <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm of SJM Quartet™ LV Lead Model 1458Q</title>
            <description>Enrolled in the treatment arm were patients implanted with the commercial SJM Quartet™ LV lead model 1458Q and any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)</title>
          <description>The primary safety endpoint is the number of participants with LV lead-related SADEs compared to the total number of analyzed participants.</description>
          <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Effective LV Pacing</title>
        <description>The effectiveness endpoint is the number of participants with effective LV pacing compared to the total number of analyzed participants. The following must be met to be considered effective LV pacing:&#xD;
Pacing threshold (immediately after implant): for pacing threshold at a pulse width of 0.5 ms, the voltage must be ≤3.5 Voltage (V) in any LV lead vector.&#xD;
Pacing stability (pre-discharge, 3 months and 6 months after implant): for pacing threshold at a pulse width of 0.5 ms, the voltage must be ≤6.0V in any LV lead vector.&#xD;
Pacing impedance (immediately after implant): Impedance value in any LV lead vector must be in the normal range of 200-2000 ohm (Ω).&#xD;
Table 9: Impedance stability (pre-discharge, 3 months and 6 months after implant): Impedance value in any LV lead vector must be in the normal range of 200-2000Ω.</description>
        <time_frame>6 months</time_frame>
        <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm of SJM Quartet™ LV Lead Model 1458Q</title>
            <description>Enrolled in the treatment arm were patients implanted with the commercial SJM Quartet™ LV lead model 1458Q implanted and any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Effective LV Pacing</title>
          <description>The effectiveness endpoint is the number of participants with effective LV pacing compared to the total number of analyzed participants. The following must be met to be considered effective LV pacing:&#xD;
Pacing threshold (immediately after implant): for pacing threshold at a pulse width of 0.5 ms, the voltage must be ≤3.5 Voltage (V) in any LV lead vector.&#xD;
Pacing stability (pre-discharge, 3 months and 6 months after implant): for pacing threshold at a pulse width of 0.5 ms, the voltage must be ≤6.0V in any LV lead vector.&#xD;
Pacing impedance (immediately after implant): Impedance value in any LV lead vector must be in the normal range of 200-2000 ohm (Ω).&#xD;
Table 9: Impedance stability (pre-discharge, 3 months and 6 months after implant): Impedance value in any LV lead vector must be in the normal range of 200-2000Ω.</description>
          <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants in Each NYHA Functional Class</title>
        <description>This secondary objective is to count the number of participants in each NYHA functional class at 6 months; NYHA classification is determined by a physician and measures the severity of a patient's heart failure by evaluating heart failure symptoms and limitations. Class I patients have mild heart failure symptoms, while patients with Class IV have severe symptoms.</description>
        <time_frame>6 months</time_frame>
        <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm of SJM Quartet™ LV Lead Model 1458Q</title>
            <description>Enrolled in the treatment arm were patients implanted with the commercial SJM Quartet™ LV lead model 1458Q and any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants in Each NYHA Functional Class</title>
          <description>This secondary objective is to count the number of participants in each NYHA functional class at 6 months; NYHA classification is determined by a physician and measures the severity of a patient's heart failure by evaluating heart failure symptoms and limitations. Class I patients have mild heart failure symptoms, while patients with Class IV have severe symptoms.</description>
          <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Not Done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Intrinsic QRS Duration of Participants</title>
        <description>This secondary objective is to measure the intrinsic QRS duration of participants at 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm of SJM Quartet™ LV Lead Model 1458Q</title>
            <description>Enrolled in the treatment arm were patients implanted with the commercial SJM Quartet™ LV lead model 1458Q and any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).</description>
          </group>
        </group_list>
        <measure>
          <title>The Intrinsic QRS Duration of Participants</title>
          <description>This secondary objective is to measure the intrinsic QRS duration of participants at 6 months.</description>
          <population>Only subjects with data available for all evaluation time points (implant, pre-discharge, 3 months and 6 months) were considered evaluable and included in the analysis.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.9" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The mean change in QRS duration between Baseline and 6 months</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.6</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety surveillance of subjects started at enrollment and continued for at least 6 months post-enrollment for all subjects, unless the subject was withdrawn from the study or died prior to the 6-month visit. If a subject was retrospectively enrolled, the investigator reported any adverse events which occurred between the implant and the date of enrollment according to the protocol. Sites continued to collect adverse event data in subjects following the 6-month visit until the study completed.</time_frame>
      <desc>Clinical sites were required to report the following events to the Sponsor:&#xD;
All Adverse Device Effects (ADEs), including procedure-related events&#xD;
All Serious Adverse Devise Effects (SADEs) including procedure-related events&#xD;
All deaths</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>This post-market study was conducted as required by China FDA to characterize the safety and efficacy of the commercial SJM Quartet™ LV lead model 1458Q implanted with any commercial SJM Unify Quadra CRT-D device or newer SJM quadripolar system (CRT-D or CRT-P).&#xD;
This is a single arm study.&#xD;
The first subject was enrolled on December 25, 2014 and the last subject was enrolled on March 25, 2016.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>three events were assessed as a pocket infection,2 events were related to PG ,1event was related to system</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax/Hemothorax</sub_title>
                <description>chest x-ray showed that a pneumothorax had developed on the left side. The subject was successfully treated with closed thoracic drainage then discharged. This event was related to procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Lead Dislodgement</sub_title>
                <description>Two events were lead dislodgments and are adjudicated as related to the Quartet™ 1458Q LV lead, other event are adjudicated as related to Right Ventricular (RV) Lead</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hematoma/Seroma</sub_title>
                <description>subject was diagnosed with pocket hematoma/seroma. This was treated by draining approximately 20ml of clear fluid from the pocket and the administration of prophylactic antibiotics.This event was related to PG</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Inappropriate Shocks</sub_title>
                <description>inappropriate shock is the most frequently reported SADE, occurring in 3.3% (4/120) of enrolled subjects and none were due to the Quartet™ 1458Q LV lead. 4 events were related to Pulse Generator (PG). 1event was related to RV lead.</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rise in Threshold and Exit Block</sub_title>
                <description>This event was related to RV Lead</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>One subject developed a pocket infection three days post-implant and was successfully treated with antibiotics. This event was related to PG</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax/Hemothorax</sub_title>
                <description>subject complained of breathing-related chest pain in the post-operative setting. A chest x-ray revealed left-sided pleural effusion, which was successfully treated by non-invasive means. This event was related to procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clay Cohorn, Clinical Program Director</name_or_title>
      <organization>Cardiac Rhythm Management, Abbott Medical Devices</organization>
      <phone>+19723098087</phone>
      <email>clay.cohorn@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

